Dianthus Therapeutics DEF 14A: Executive Compensation Details
Ticker: DNTH · Form: DEF 14A · Filed: Apr 10, 2025 · CIK: 1690585
| Field | Detail |
|---|---|
| Company | Dianthus Therapeutics, INC. /De/ (DNTH) |
| Form Type | DEF 14A |
| Filed Date | Apr 10, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-compensation, def-14a, equity-awards
TL;DR
Dianthus exec comp filing out. Ryan Savitz & Marino Garcia got equity. Magenta Therapeutics is old name.
AI Summary
Dianthus Therapeutics, Inc. filed a DEF 14A on April 10, 2025, detailing executive compensation for the fiscal year ending December 31, 2024. Key individuals like Ryan Savitz and Marino Garcia received equity awards. The filing also notes a former company name, Magenta Therapeutics, Inc., which changed on November 21, 2016.
Why It Matters
This filing provides transparency into how Dianthus Therapeutics compensates its top executives, which can influence investor decisions and perceptions of company management.
Risk Assessment
Risk Level: low — This is a routine DEF 14A filing detailing executive compensation and does not present immediate financial risks.
Key Numbers
- 2024-12-31 — Fiscal Year End (Reporting period for compensation details)
- 20250410 — Filing Date (Date the DEF 14A was submitted)
- 20161121 — Name Change Date (Date Dianthus Therapeutics changed from Magenta Therapeutics, Inc.)
Key Players & Entities
- Dianthus Therapeutics, Inc. (company) — Filer
- Ryan Savitz (person) — Member receiving equity awards
- Marino Garcia (person) — Member receiving equity awards
- Magenta Therapeutics, Inc. (company) — Former company name
- Dr Jason Gardner (person) — Member
- Stephen Mahoney (person) — Member
FAQ
What was the total value of equity awards granted to Ryan Savitz in the covered year?
The filing indicates equity awards granted to Ryan Savitz for the year ending December 31, 2024, but the specific dollar amount is not detailed in this excerpt.
What is the primary business of Dianthus Therapeutics, Inc.?
Dianthus Therapeutics, Inc. is in the Pharmaceutical Preparations industry (SIC code 2834).
Who is Marino Garcia and what role did he play in relation to equity awards?
Marino Garcia is listed as a Member, and the filing details his equity awards granted and vested, as well as changes in the fair value of outstanding and unvested equity awards.
When did the company change its name from Magenta Therapeutics, Inc.?
The company's name changed from Magenta Therapeutics, Inc. on November 21, 2016.
What is the business address of Dianthus Therapeutics, Inc.?
The business address is 7 Times Square, 43rd Floor, New York, NY 10036.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 10, 2025 by Ryan Savitz regarding Dianthus Therapeutics, Inc. /DE/ (DNTH).